8-K: Rhythm Pharma Reports Strong Q4, FY25 Revenue; Key Milestones Ahead

Rhythm Pharmaceuticals announced preliminary unaudited Q4 and full-year 2025 net product revenues for IMCIVREE, showing significant growth, alongside upcoming clinical and regulatory milestones.

Summary

• Preliminary unaudited net product revenues from global sales of IMCIVREE were approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025.
• Preliminary unaudited net product revenues for the full year of 2025 were approximately $194 million, representing a 50% increase from the full year 2024's $130 million.
• U.S. sales of IMCIVREE contributed approximately 68% of fourth quarter and 69% of full-year 2025 preliminary unaudited net product revenues.
• The PDUFA goal date for the sNDA for setmelanotide in acquired hypothalamic obesity is March 20, 2026.
• Topline data from the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired hypothalamic obesity is on track to be reported in the first quarter of 2026.
• Topline data from the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases is on track to be reported in the first quarter of 2026.
• Positive preliminary data for the exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS) was announced in December 2025, showing BMI and hyperphagia reductions at month 3 and month 6, with a consistent safety profile.
• The company anticipates announcing six-month results from 18 patients from the ongoing Phase 2 PWS trial in the first half of 2026.
• Enrollment in the setmelanotide Phase 3 trial substudy in congenital hypothalamic obesity is expected to be completed in the first half of 2026.
• A pivotal Phase 3 trial evaluating the oral MC4R agonist, bivamelagon, in acquired hypothalamic obesity is planned to be initiated in 2026, pending regulatory feedback.
• Enrollment in the Phase 1, Part C trial evaluating the weekly MC4R agonist RM-718 in patients with acquired hypothalamic obesity is expected to be completed in the first quarter of 2026.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth for IMCIVREE, significant progress in multiple clinical trials, and a clear path to potential market expansion with the upcoming PDUFA date for acquired hypothalamic obesity. The company is well-capitalized, with cash sufficient for over 24 months of operations. While preliminary, the financial and clinical updates are overwhelmingly positive, indicating strong operational execution and future growth potential, despite the inherent risks of drug development and regulatory approval.

Positives

• Strong preliminary Q4 2025 net product revenue of $57 million, an 11% sequential increase over Q3 2025.
• Significant preliminary FY 2025 net product revenue of $194 million, a 50% year-over-year increase from $130 million in FY2024.
• Consistent growth in both U.S. and international markets, driven by increased patients on reimbursed therapy and improved access to IMCIVREE.
• PDUFA goal date set for March 20, 2026, for setmelanotide in acquired hypothalamic obesity, indicating potential near-term market expansion.
• Positive preliminary data from the exploratory Phase 2 trial of setmelanotide in Prader-Willi Syndrome, showing BMI and hyperphagia reductions at months 3 and 6, with a consistent safety profile.
• Anticipated topline data readouts for key Phase 3 trials (Japanese HO cohort, EMANATE) in Q1 2026.
• Cash, cash equivalents, and short-term investments of $416.1 million as of September 30, 2025, sufficient to fund planned operations for at least 24 months.
• IMCIVREE is the first and only FDAand EMA-approved therapy targeting early-onset, severe obesity and hyperphagia associated with BBS, POMC, PCSK1, or LEPR deficiencies.
• Setmelanotide demonstrated statistically significant and clinically meaningful reduction in BMI in Phase 3 Acquired HO trial (-19.8% placebo-adjusted difference, P<0.0001).
• BMI reductions in Acquired HO trial were consistent across stratified age groups (<12 Yrs: -19.5%, 12-<18 Yrs: -21.0%, >=18 Yrs: -19.2%, all P<0.0001).
• Significant BMI reductions observed in Acquired HO patients with prior or concomitant use of GLP-1s (-24.7% and -27.1% placebo-adjusted differences, respectively).
• Bivamelagon achieved statistically significant BMI reductions at all tested doses in Phase 2 HO trial (200mg: -2.68%, 400mg: -7.69%, 600mg: -9.31% mean reductions, all P<0.0180).
• Bivamelagon's BMI reductions were consistent with setmelanotide.
• HQ-CT1 scores showed meaningful hyperphagia reductions in 6 of 7 evaluable PWS patients at Month 3.
• Positive body composition changes (greater decreases in total fat mass vs. lean muscle mass) observed in PWS patients at Month 6.
• DAYBREAK Phase 2 trial data showed 84% of patients on continuous setmelanotide achieved or maintained >5% BMI reduction from baseline (mean -12.4% BMI change).
• German investigator-led study showed setmelanotide associated with improvement in MASLD and kidney function in BBS patients.
• French early-access program data showed mean BMI reductions of -5.6% at Month 1, -12.8% at Month 3, and -21.3% at Month 6 in acquired HO patients.
• Real-world case reports from French early-access program suggest setmelanotide may be effective for congenital HO.
• Rapid and statistically significant hunger reduction in HO patients aged 12+ years (P=0.0086 vs placebo).
• Consistent response to setmelanotide therapy observed across majority of patients in Phase 3 Acquired HO trial, with high proportions achieving BMI reductions (e.g., 80% achieving >=5% reduction vs 5% for placebo, P<0.0001).
• Hypothalamic Obesity patients achieved 25.5% mean BMI reduction at one year of setmelanotide therapy in long-term extension trial.
• Three of 11 pediatric patients achieved normal weight at one year in Acquired HO trial.

Negatives

• Preliminary financial results are unaudited and subject to change upon completion of financial close and audit procedures.
• The SRC1 and LEPR substudies within the EMANATE trial are currently under-enrolled, potentially requiring additional studies to seek regulatory approval.
• Setmelanotide is not indicated for obesity due to suspected POMC, PCSK1, or LEPR deficiency with variants classified as benign or likely benign, or other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency.
• Contraindication for prior serious hypersensitivity to setmelanotide or any excipients.
• Warnings and precautions include disturbance in sexual arousal, depression and suicidal ideation, hypersensitivity reactions, skin hyperpigmentation, darkening of pre-existing nevi, and risk of serious adverse reactions due to benzyl alcohol preservative in neonates and low birth weight infants.
• Treatment with IMCIVREE is not recommended when breastfeeding; discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

Risks

• Actual financial results for the fourth quarter and full year 2025 may differ from preliminary estimates due to incomplete financial closing and audit procedures.
• Ability to enroll patients in clinical trials.
• Design and outcome of clinical trials.
• Impact of competition.
• Ability to achieve or obtain necessary regulatory approvals.
• Risks associated with data analysis and reporting.
• Unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Risks associated with the laws and regulations governing international operations and the costs of any related compliance programs.
• Ability to successfully commercialize setmelanotide.
• Liquidity and expenses.
• Ability to retain key employees and consultants, and to attract, retain, and motivate qualified personnel.
• General economic conditions.
• Failure to identify and develop additional product candidates.
• Risks relating to product liability lawsuits.
• Inability to maintain collaborations, or the failure of these collaborations.
• Reliance on third parties.
• Risks relating to intellectual property.
• Risks related to internal control over financial reporting.

Future Outlook

Rhythm Pharmaceuticals is focused on delivering sustainable, long-term growth, preparing for the U.S. launch of IMCIVREE for acquired hypothalamic obesity pending FDA approval, and anticipating topline data readouts from key Phase 3 trials in Q1 2026. The company also plans to initiate a Phase 3 trial for bivamelagon in acquired HO and advance setmelanotide and RM-718 for Prader-Willi syndrome. Cash reserves are projected to fund operations for at least 24 months.

Management Comments

• "2025 was a year of strong execution and reflects significant progress toward our mission of transforming the lives of patients with rare neuroendocrine diseases." David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm.
• "Our preliminary fourth quarter and full-year 2025 net product revenues reflect consistent growth in both the United States and international markets, driven by a steady increase in patients on reimbursed therapy and continued progress in securing access to IMCIVREE." David Meeker, M.D.
• "Looking ahead, we are focused on delivering sustainable, long-term growth as we prepare to launch IMCIVREE for patients with acquired hypothalamic obesity (HO) in the United States, pending FDA approval." David Meeker, M.D.
• "Additionally in 2026, we are excited about top-line data readouts from the Japanese cohort of our Phase 3 trial in acquired HO and the Phase 3 EMANATE trial, initiating a Phase 3 trial to evaluate our oral MC4R agonist, bivamelagon, in acquired HO and advancing setmelanotide and RM-718 for patients with Prader-Willi syndrome." David Meeker, M.D.

Industry Context

The biopharmaceutical industry is increasingly focusing on rare diseases and genetic conditions, where unmet medical needs are high. Rhythm Pharmaceuticals' work with MC4R agonists like setmelanotide, bivamelagon, and RM-718 positions it within the specialized segment of neuroendocrine diseases and genetic forms of obesity. The potential expansion into acquired hypothalamic obesity and Prader-Willi syndrome addresses significant patient populations with limited therapeutic options, aligning with a broader industry trend of developing targeted therapies for specific genetic or acquired conditions. The mention of GLP-1s in the context of setmelanotide efficacy highlights the competitive landscape in obesity treatment, where MC4R agonists offer a distinct mechanism for specific patient groups.

Comparison to Industry Standards

• Setmelanotide demonstrated significant BMI reductions in acquired HO patients, even those with prior or concomitant use of GLP-1s (-24.7% and -27.1% placebo-adjusted differences, respectively). This suggests setmelanotide offers a distinct and effective mechanism of action that can complement or surpass the effects of GLP-1 receptor agonists, which are a major class of obesity drugs.
• The efficacy of setmelanotide in acquired HO, with a -19.8% placebo-adjusted BMI reduction, compares favorably to many general obesity treatments, especially given the severity and intractability of HO.
• The positive preliminary data for setmelanotide in Prader-Willi Syndrome, showing BMI and hyperphagia reductions, addresses a condition with very limited effective therapeutic options, positioning setmelanotide as a potential breakthrough in an area of high unmet need.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, promising clinical pipeline, and potential market expansion, which could lead to increased share value.
• Patients: Significant positive impact through the development and potential approval of new treatments for rare neuroendocrine diseases and severe obesity conditions like acquired hypothalamic obesity and Prader-Willi syndrome, offering hope where current options are limited.
• Employees: Positive impact from company growth and pipeline advancement, potentially leading to job security and expansion opportunities.
• Healthcare Providers: New therapeutic options for challenging patient populations, enhancing their ability to manage complex conditions.
• Regulatory Authorities: Continued engagement with FDA and European agencies for approvals and clinical trial oversight.

Next Steps

• Launch IMCIVREE in the United States for acquired hypothalamic obesity, pending FDA approval (PDUFA goal date March 20, 2026).
• Announce topline data from the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO in Q1 2026.
• Announce topline data from the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in Q1 2026.
• Report fourth quarter and full year 2025 financial results in late February 2026.
• Complete enrollment in the setmelanotide Phase 3 trial substudy in congenital HO in H1 2026.
• Announce six-month results from 18 patients from the ongoing Phase 2 trial in Prader-Willi Syndrome in H1 2026.
• Initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO in 2026, pending regulatory feedback.
• Complete enrollment in the Phase 1, Part C trial evaluating RM-718 in patients with acquired HO in Q1 2026.
• Complete enrollment in Part D of Phase 1/2 trial evaluating RM-718 in PWS in 2026.

Key Dates

Recommendation

The filing presents exceptionally strong preliminary financial results with significant year-over-year and sequential revenue growth for IMCIVREE. The company has a robust clinical pipeline with multiple near-term catalysts, including a PDUFA goal date for a major new indication (acquired hypothalamic obesity) and topline data readouts for two Phase 3 trials in Q1 2026. Positive preliminary data for Prader-Willi Syndrome further de-risks the pipeline. With over $416 million in cash, the company is well-funded for its planned operations for at least 24 months. These factors collectively indicate strong operational execution, significant growth potential, and a favorable risk-reward profile for investors, warranting a strong buy recommendation.

Keywords

Rhythm Pharmaceuticals, RYTM, IMCIVREE, setmelanotide, MC4R agonist, hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome, POMC deficiency, LEPR deficiency, PCSK1 deficiency, EMANATE trial, bivamelagon, RM-718, rare neuroendocrine diseases, obesity, hyperphagia, biopharmaceutical, FDA approval, PDUFA, clinical trials, financial results, revenue, Q4 2025, FY 2025